A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
Arif Manji,Irene Brana,Eitan Amir,George Tomlinson,Ian F. Tannock,Philippe L. Bedard,Amit M. Oza,Lillian L. Siu,Albiruni Ryan Abdul Razak +8 more
TL;DR: The utilization of expansion cohorts has increased with time and may provide useful supplementary data for phase I trials, particularly with regard to toxicity and definition of recommended dose for phase II studies.
Journal ArticleDOI
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer.
Hui K Gan,Lori J. Bernstein,Jennifer Brown,Jolie Ringash,Mehrdad Vakilha,Lisa Wang,David Goldstein,John Kim,Andrew Hope,Brian O'Sullivan,John Waldron,Albiruni Ryan Abdul Razak,Eric X. Chen,Lillian L. Siu +13 more
TL;DR: Neuropsychological testing is feasible in squamous cell carcinoma of the head-and-neck survivors and the findings were suggestive of treatment-related cognitive dysfunction, which warrant additional investigation.
Journal ArticleDOI
Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hans J. Hammers,Elizabeth R. Plimack,Jeffrey R. Infante,Brian I. Rini,David F. McDermott,Marc S. Ernstoff,Martin H. Voss,Padmanee Sharma,Sumanta K. Pal,Albiruni Ryan Abdul Razak,Christian K. Kollmannsberger,Daniel Y.C. Heng,Jennifer L. Spratlin,Yun Shen,Paul Gagnier,Asim Amin +15 more
TL;DR: Nivolumab (N), a fully human IgG4 immune checkpoint inhibitor antibody, has shown durable response and encouraging overall survival (OS) in mRCC.
Journal ArticleDOI
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter,Philippe L. Bedard,Eric Chen,Blaise Clarke,Ben Tran,Sebastien J. Hotte,Anastasios Stathis,Hal W. Hirte,Albiruni Ryan Abdul Razak,Michael Reedijk,Zhuo Chen,Brenda Cohen,Wenjiang Zhang,Lisa Wang,S. Percy Ivy,Malcolm J. Moore,Amit M. Oza,Lillian L. Siu,Elaine McWhirter +18 more
TL;DR: Although RO exposure was limited by the presence of autoinduction, RO levels achieved exceeded the area under the concentration-time curve for 0–24 h (AUC0–24) predicted for efficacy in preclinical models using daily dosing.
Journal ArticleDOI
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
Stuart J. Wong,Theodore Karrison,David N. Hayes,Merrill S. Kies,Kevin J. Cullen,Tawee Tanvetyanon,Athanassios Argiris,Naoko Takebe,D. Lim,Nabil F. Saba,Frank Worden,Jill Gilbert,Heinz-Josef Lenz,Albiruni Ryan Abdul Razak,John D. Roberts,Everett E. Vokes,Ezra E.W. Cohen +16 more
TL;DR: Although there was only one objective response, dasatinib is well tolerated, with tumor stabilization achieved by 50% of ACC patients, and Dasatinib demonstrated no activity in non-ACC MSGT.